Picture of Egetis Therapeutics AB (publ) logo

EGTX Egetis Therapeutics AB (publ) Income Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for Egetis Therapeutics AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

2019
December 31st
R2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue82.640.738.222.657.6
Cost of Revenue
Gross Profit38.830.416.346.6
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses149218144221382
Operating Profit-66.7-177-106-198-325
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-61.4-178-105-194-327
Provision for Income Taxes
Net Income After Taxes-61.4-178-105-194-327
Net Income Before Extraordinary Items
Net Income-61.4-178-105-194-327
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-61.4-178-105-194-327
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.08-2.42-0.581-0.998-1.27
Dividends per Share